Advertisement

Topics

Latest "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Stories

05:14 EST 4th December 2016 | BioPortfolio

Here are the most relevant search results for "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" found in our extensive news archives from over 250 global news sources.

More Information about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine for you to read. Along with our medical data and news we also list autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Clinical Trials, which are updated daily. BioPortfolio also has a large database of autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Companies for you to search.

Showing "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Articles 1–25 of 14,000+

Extremely Relevant

Epstein–Barr virus: more than 50 years old and still providing surprises

This Timeline article describes the discovery of the Epstein–Barr virus and summarizes the key advances in the field that have led to our current understanding of the role this virus plays in a number of different lymphoid and epithelial malignancies.


Can Epstein-Barr Virus Increase Breast Cancer Risk?

Epstein-Barr Virus might increase the risk of breast cancer, according to experiments with cell lines and mouse xenografts that identified a potential mechanism for the suspected link.

Scientists uncover how common Epstein-Barr virus causes blood cancer in adults and children

Scientists at the University of Sussex, trying to uncover how the common Epstein-Barr virus causes blood cancer in adults and children, have discovered how the virus takes control of two genes involved in cancer development so it can switch them on or off.


Epstein-Barr virus-encoded miR-BART6-3p inhibits cancer cell metastasis and invasion by targeting long non-coding RNA LOC553103

Association of Epstein–Barr virus reactivation with the recovery of CD4/CD8 double-negative T lymphocytes after haploidentical hematopoietic stem cell transplantation

Eppstein Barr virus may promote breast cancer development

New research reveals that infection with the Epstein-Barr virus (EBV) may put some women at increased risk for developing breast cancer. The findings, published online in the July issue of the journal EBioMedicine, may have important implications for...

EBV-derived microRNAs silence immune alarm signals of the host cell

Epstein-Barr virus (EBV) prevents infected cells from being attacked by the immune system. The virus drives production of small molecules, so-called microRNAs, that suppress alarm signals sent out by the infected cell. Scientists at Helmholtz Zentrum München have elucidated this previously unknown mechanism.

How a common virus triggers blood cancer

Scientists trying to uncover how the common Epstein-Barr virus causes blood cancer in adults and children, have discovered how the virus takes control of two genes involved in cancer development so it can switch them on or off.

“Kissing Disease” Virus Promotes Malignant Breast Cancer Development

In our adolescent years, we would often snicker at other kids who were diagnosed with mononucleosis, as it was (and often still is) colloquial referred to as the “kissing disease.” However, in recent years mounting evidence has suggested that infection with Epstein-Barr virus (EBV) has become associated with various forms of cancer—which is certainly no laughing matter. Alarm...

Common virus triggers blood cancer

Scientists at the University of Sussex, trying to uncover how the common Epstein-Barr virus causes blood cancer in adults and children, have discovered how the virus takes control of two genes involved in cancer development so it can switch them on or...

Scientists reveal how a common virus triggers blood cancer

Scientists at the University of Sussex, trying to uncover how the common Epstein-Barr virus causes blood cancer in adults and children, have discovered how the virus takes control of two genes involved in cancer development so it can switch them on or off.

Atara Bio Announces Clinical Trial Results for the Treatment of EBV+ Nasopharyngeal Carcinoma using Allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte Product Candidate

SOUTH SAN FRANCISCO, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life threatening diseases that have been underserved by scientific innovation, today announced that its collaborating investigators at Memorial Sloan Kettering Cancer Center (MSK) reported ...

Atara Bio Receives Advanced Therapy Medicinal Product Classification for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) from European Medicines Agency (EMA)

SOUTH SAN FRANCISCO, Calif., June 23, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced that the EMA has classified the Company’s EBV-CTL product candidate as an Advanced Therapy Medicinal Product (ATMP) that falls within the defini...

Medical News Today: What is Mono and Should I Worry About It?

Learn all about mono, a condition that is often caused by the Epstein-Barr virus. This article looks at the symptoms, causes, treatment, and prevention.

Atara Bio Doses First Patient in Multi-Center Expanded Access Protocol for Study of Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) in EBV-Associated Lymphomas and Lymphoproliferative Disorders

SOUTH SAN FRANCISCO, Calif., July 12, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases, today announced the dosing of its first patient in the multi-center Expanded Access Protocol (EAP) for Study of Allogeneic EBV-CTLs in EBV-Associated Lymphomas an...

Atara Bio Granted Access to Priority Medicines (PRIME) Regulatory Support for Allogeneic Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes (CTL) for Treatment of EBV-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD)

SOUTH SAN FRANCISCO, Calif., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) and Commit...

How Epstein-Barr Virus Hijacks B Cells To Cause Blood Cancer

Scientists describe a mechanism by which EBV controls the expression of two genes, leading B cells to replicate out of control and avoid apoptosis.

Glioblastoma Survival Linked to Insurance Status: Oncotherapy Network & Cancer Network

(MedPage Today) -- Also, Epstein-Barr Virus associated with breast cancer risk?

Cognate to make dendritic cell cancer vaccine in $2.2m deal with Astorias

Asterias Biotherapeutics has selected Cognate BioServices for the process development and manufacture of its autologous dendritic cell vaccine candidate, AST-VAC1.

Cognate to make dendritic cell cancer vaccine in $2.2m deal with Asterias

Asterias Biotherapeutics has selected Cognate BioServices for the process development and manufacture of its autologous dendritic cell vaccine candidate, AST-VAC1.

CANCER: Le virus herpès qui prédispose les cellules mammaires à devenir malignes - EBioMedicine

Une nouvelle étude révèle que l'infection par le virus d'Epstein-Barr (VEB), un virus de de la famille des herpès virus humains peut augmenter, chez les femmes, le risque de développer un cancer du sein. Ainsi, les chercheurs de Boston montrent in vitro et in vivo, que l'infection à VEB prédispose les cellules mammaires à devenir malignes. De...

New evidence links Zika, Guillain-Barré syndrome

In a collaborative effort with scientists at six Colombian hospitals, Johns Hopkins researchers report what they believe to be the strongest biological evidence to date linking Zika virus infection and Guillain-Barré syndrome. Epidemiology data have long suggested a close relationship between rising Zika virus infection rates and instances of Guillain-Barré. The new study’s results, ...

One of the most common viruses in humans may promote breast cancer development

New research reveals that infection with the Epstein-Barr virus (EBV) may put some women at increased risk for developing breast cancer. The findings, published online in the July issue of the journal EBioMedicine, may have important implications for breast cancer screening and prevention.

Advances toward potential Zika virus vaccine development

A promising Zika virus vaccine has now been developed, report scientists. The vaccine, a DNA vaccine, is safer and more effective against Zika virus and could offer more affordable long-term protection, researchers report.

Three Investigational Vaccine Platforms Induced Immune Responses Against Zika Virus

Three different investigational Zika virus vaccine platforms--an inactivated virus vaccine, a DNA-based vaccine, and an adenovirus vector-based vaccine--protected against infection, induced immune responses, and produced no adverse side effects when tested in rhesus macaques challenged with the Zika virus, according to findings appearing August 4


Quick Search
Advertisement
 

News Quicklinks